Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1802148-05-5
Molecular formula
C23H24N4O4
Molecular weight
420.5 g/mol
Drug class
Dipeptidyl peptidase 1 (DPP1) inhibitoranti-inflammatory small molecule
Mechanism of action
Competitively and reversibly inhibits DPP1, the enzyme that activates neutrophil serine proteases during neutrophil maturation. DPP1 inhibition reduces activity of neutrophil elastase, cathepsin G and proteinase 3, which contribute to neutrophil-mediated inflammation in bronchiectasis.
Indications / reported uses
Treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and paediatric patients aged 12 years and older under the US FDA Brinsupri indication
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Brensocatib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Brensocatib Permitted Daily Exposure (PDE) report (the Brensocatib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Brensocatib Occupational Exposure Limit (OEL) report (the Brensocatib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.